Literature DB >> 2847928

Effect of clonidine on beta-endorphin, ACTH and cortisol secretion in essential hypertension and obesity.

J Słowinska-Srzednicka1, S Zgliczynski, P Soszynski, J Puciłowska, M Wierzbicki, W Jeske.   

Abstract

The role of alpha 2-adrenoceptor stimulation by clonidine on the secretion of beta-endorphin, ACTH, and cortisol in essential hypertension and obesity was studied in 45 subjects: 15 non-obese hypertensives, 10 obese hypertensives, 11 obese normotensives, and 9 healthy subjects. The circadian rhythm of plasma beta-endorphin, ACTH, and cortisol was determined after placebo and after three days on clonidine 0.45 mg daily. Clonidine lowered the blood pressure and blood ACTH and cortisol levels in all the subjects. A significant decrease in beta-endorphin after clonidine occurred in the healthy subjects. In obese normotensives basal beta-endorphin concentrations were significantly higher than in healthy subjects and did not change after clonidine. In about 50% of non-obese and obese hypertensives a significant increase in beta-endorphin secretion after clonidine was noted (responders). In the subgroup of non-obese hypertensive responders no circadian rhythm of beta-endorphin was observed. The results suggest that adrenergic regulation of beta-endorphin secretion is altered in obesity and in certain patients with essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2847928     DOI: 10.1007/bf00609239

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  38 in total

1.  Central alpha-activation by clonidine reduces plasma level of beta-endorphin in patients with essential hypertension.

Authors:  K Yasunari; Y Kanayama; M Kohno; K Murakawa; T Kawarabayashi; T Takeda; N Kotsugai; K Sato
Journal:  Life Sci       Date:  1985-10-21       Impact factor: 5.037

2.  An inhibitory role of beta-endorphin in central cardiovascular regulation.

Authors:  M A Petty; W de Jong; D de Wied
Journal:  Life Sci       Date:  1982-05-24       Impact factor: 5.037

3.  Development of a non-extracted 'two-site' immunoradiometric assay for corticotropin utilizing extreme amino- and carboxy-terminally directed antibodies.

Authors:  S C Hodgkinson; B Allolio; J Landon; P J Lowry
Journal:  Biochem J       Date:  1984-03-15       Impact factor: 3.857

Review 4.  The opioid system in cardiac and vascular regulation of normal and hypertensive states.

Authors:  G Feuerstein; A L Sirén
Journal:  Circulation       Date:  1987-01       Impact factor: 29.690

5.  beta-Endorphin and adrenocorticotropin are selected concomitantly by the pituitary gland.

Authors:  R Guillemin; T Vargo; J Rossier; S Minick; N Ling; C Rivier; W Vale; F Bloom
Journal:  Science       Date:  1977-09-30       Impact factor: 47.728

6.  Systemic administration of beta-endorphin: potent hypotensive effect involving a serotonergic pathway.

Authors:  I Lemaire; R Tseng; S Lemaire
Journal:  Proc Natl Acad Sci U S A       Date:  1978-12       Impact factor: 11.205

7.  Reversal by naloxone of the antihypertensive action of clonidine: involvement of the sympathetic nervous system.

Authors:  C Farsang; J Kapocsi; L Vajda; K Varga; Z Malisak; M Fekete; G Kunos
Journal:  Circulation       Date:  1984-03       Impact factor: 29.690

8.  beta-Endorphin in the human pancreas.

Authors:  J F Bruni; W B Watkins; S S Yen
Journal:  J Clin Endocrinol Metab       Date:  1979-10       Impact factor: 5.958

9.  Naloxone does not modify the hemodynamic and neuroendocrine effects of clonidine in normal humans.

Authors:  R Pedrinelli; G P Bernini; A Salvetti
Journal:  J Cardiovasc Pharmacol       Date:  1985 Sep-Oct       Impact factor: 3.105

10.  Diurnal rhythm of beta endorphin in normotensive and hypertensive patients: the effect of clonidine.

Authors:  C Farsang; L Vajda; J Kapocsi; Z Malisák; S Alföldi; K Varga; I Juhász; G Kunos
Journal:  J Clin Endocrinol Metab       Date:  1983-04       Impact factor: 5.958

View more
  5 in total

Review 1.  Drugs and HPA axis.

Authors:  Alberto Giacinto Ambrogio; Francesca Pecori Giraldi; Francesco Cavagnini
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

2.  Neurohormonal and metabolic effects of medetomidine compared with xylazine in healthy cats.

Authors:  Teppei Kanda; Yoshiaki Hikasa
Journal:  Can J Vet Res       Date:  2008-04       Impact factor: 1.310

3.  The effects of glucose ingestion and fasting on plasma immunoreactive beta-endorphin, adrenocorticotropic hormone and cortisol in obese subjects.

Authors:  S Balon-Perin; J Kolanowski; A Berbinschi; P Franchimont; J M Ketelslegers
Journal:  J Endocrinol Invest       Date:  1991-12       Impact factor: 4.256

4.  Effects of 2 different medetomidine infusion rates on selected neurohormonal and metabolic parameters in dogs.

Authors:  Leigh Lamont; Shelley Burton; Deanne Caines; Elmabrok Masaoud; Eric Troncy
Journal:  Can J Vet Res       Date:  2012-04       Impact factor: 1.310

5.  Neurohormonal and metabolic effects of medetomidine compared with xylazine in beagle dogs.

Authors:  T D Ambrisko; Y Hikasa
Journal:  Can J Vet Res       Date:  2002-01       Impact factor: 1.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.